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Calcineurin inhibitors potentially prevent pro-allergic mediator release from basophils
and mast cells but are rarely used systemically due to ubiquitous expressions of
target signaling proteins. However, specific targeting of allergic effector cells with
these inhibitors could circumvent unwanted side effects. We recently demonstrated the
biocompatibility of gold nanoparticles (AuNPs) as a platform for non-toxic delivery of
signaling inhibitors due to unique physicochemical properties of these nanomaterials.
Since AuNPs can be conjugated with both anti-allergic drugs and antibodies or other
proteins that specifically recognize basophils and mast cells, our aims were to assess
specific targeting of allergic effector cell function using AuNPs conjugated with the
calcineurin inhibitor ascomycin. Purified human basophils and LAD2 human mast cells
were used for investigations with AuNPs conjugated either to CD203c antibodies or
containing stem cell factor (SCF), respectively, which were amine-coupled to acidic
groups of reduced glutathione (GSH). GSH was also used as a spacer for immobilization
of ascomycin on the gold surface. AuNPs conjugated with anti-CD203c and ascomycin
strikingly blocked IgE-dependent degranulation of both purified basophils and those
present in mixed leukocyte preparations, suggesting specific targeting of these cells. In
contrast, LAD2 mast cell responses were not inhibited using anti-CD203c-containing
nanoconjugates but were when the conjugates contained SCF. Successful targeting
of allergic effector cells using gold nanoconjugates indicates that this technology may
have therapeutic potential for the treatment of allergies by specifically delivering highly
effective signaling inhibitors with reduced side effects.
Keywords: gold nanoconjugates, basophils, mast cells, ascomycin, IgE, CD203c, stem cell factor
INTRODUCTION
Inflammatory mediator release, (e.g., histamine) from basophils and mast cells plays a major
role in contributing to the symptoms of allergic reactions and these cells may also support the
underlying tendency for an individual’s immune system to respond in a pro-allergic manner
(reviewed in Varricchi et al., 2018). In terms of anti-allergic therapy, it is therefore desirable
to target these cells and limit their ability to release inflammatory and immunomodulatory
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mediators. Several pharmacological inhibitors of intracellular
signaling, (e.g., Syk and calcineurin inhibitors) have been shown
to substantially reduce the ability of mast cells and basophils
to release allergic mediators following stimulation of the high-
affinity IgE receptor (FcεRI) (Oliver et al., 1994; Zuberbier et al.,
2001; Plath et al., 2003; Matsubara et al., 2006; Rossi et al., 2006;
Harrison et al., 2007). However, due to the ubiquitous expressions
of intracellular signals systemic clinical use of these inhibitors
is problematical in terms of potential side effects and adverse
drug reactions. It is therefore desirable to be able to specifically
target effector cells involved in human allergy with drugs that are
known to prevent allergen-induced cell activation and the release
of pro-inflammatory mediators.
We recently reported the proof-of-principle that gold
nanoparticles (AuNPs) could be used to specifically target
basophils and other cell types with certain signal transduction
inhibitors (Gibbs et al., 2014; Yasinska et al., 2018). Furthermore,
compared to most other nanomaterials, AuNPs are relatively
non-toxic (Deng et al., 2011; Pissuwan et al., 2011) and are easily
conjugated with pharmacological agents and antibodies/antigen-
binding peptides (Ma et al., 2010; Gibbs et al., 2014; Yasinska et al.,
2018). Moreover, we observed that AuNPs display inherent anti-
inflammatory properties themselves by neutralizing the effects
of IL-1β (Sumbayev et al., 2013), a cytokine that contributes to
allergic inflammation, particularly in asthma.
As a specific marker for mast cells and basophils, we chose
CD203c [the ectonucleotide pyrophosphatase/phosphodiesterase
family member 3 (ENPP-3)] since it is currently the only known
membrane-associated protein that is almost exclusively expressed
on both human mast cells and basophils (Bühring et al., 2001;
Ghannadan et al., 2002). This marker has been employed in
flow cytometric assays for clinical diagnostics regarding basophil
activation (Boumiza et al., 2003; Kleine-Tebbe et al., 2006). Its
biological function in these cells is not clear but its surface
expression is upregulated by priming factors involved in allergic
diseases, such as IL-3, and during allergic responses of these cells
(Hauswirth et al., 2007; Ono et al., 2010).
Given the above statements, our main aim was to specifically
target and inhibit the function of primary human basophils
and LAD2 mast cells using AuNPs conjugated to anti-CD203c
and ascomycin. Furthermore, we characterized our AuNP-
based nanoconjugates (NCJ) using synchrotron radiation circular
dichroism (SRCD) spectroscopy. We also compared the effects
of NCJ containing anti-CD203c to those conjugated to stem cell
factor (SCF). This may allow mast cell-selective targeting since
SCF binds to KIT, a receptor that is highly expressed in mature
mast cells (other cells include immature haemopoietic stem cells,
melanocytes and interstitial cells of the Cajal).
METHODS
Generation and Characterization of NCJ
Synthesis of 5 nm AuNPs was performed essentially as described
previously (Sumbayev et al., 2013; Gibbs et al., 2014; Yasinska
et al., 2018). Briefly, 5 ml of aqueous gold (III) chloride trihydrate
(10 mM) and 2.5 ml of aqueous sodium citrate (100 mM)
were added to 95 ml of milliQ-water in a round bottom flask
equipped with a magnetic stirrer. The solution (which has a
pale yellow appearance) was cooled down to 1–2◦C. Under
vigorous stirring 1 ml of aqueous sodium borohydride (4◦C,
0.1 M) was added and the solution (which should have a
dark red appearance) was then stirred for further 10 min
on an ice bath before being allowed to warm up to room
temperature. NCJ were generated as described before using
glutathione as a linker to immobilize one molecule of anti-
CD203c antibody or SCF per 1 nanoparticle. The rest of the
surface was covered by glutathiolated (through –COOH group)
ascomycin (maximum 1,000 molecules per nanoparticle) (Gibbs
et al., 2014; Yasinska et al., 2018). The same principle was
adopted for the generation of SCF-containing NCJ (where
SCF was employed instead of anti-CD203c). Nanomaterials
were characterized using SRCD spectroscopy as described
previously (Yasinska et al., 2018).
Briefly, SRCD measurements were conducted using 10 cm
path length cell with 3 mm aperture diameter and capacity
of 800 µl using the Module B with a 1 nm increment, 1s
integration time and 1.2 nm bandwidth at 23◦C (Hussain et al.,
2012; Yasinska et al., 2018). The results obtained were analyzed
using CDAPPs program (Hussain et al., 2012, 2015) and Origin
software (OriginLabTM).
Basophil Isolation and Purification
Basophils, were isolated from buffy coat blood (purchased from
the NHS Blood and Transplant service following ethics approval
(NHS REC 12/WM/0319) by Ficoll-density centrifugation and
purified further (to>90%) by immunomagnetic cell sorting using
commercial kits, as previously described (Gibbs et al., 2008).
Basophil purities were determined by alcian blue staining.
LAD2 Mast Cells
LAD2 cells were generously provided to us by Dr. A.
Kirshenbaum and Prof. D. Metcalfe (NIH, Bethesda,
United States) and cultured in Stem-Pro-34 serum-free
media in the presence of 100 ng/ml SCF as previously reported
(Kirshenbaum et al., 2003). Human SCF protein was produced
in Escherichia Coli and purified following established protocols
(Wang et al., 2008). Cells were sensitized with 100 ng/ml
polyclonal IgE (Amsbio, Abingdon, United Kingdom) 24 h
before the experiments.
Cell Stimulation and Histamine
Release Assay
Cells were re-suspended in HEPES-buffered Tyrode’s solution
(containing 1 mM CaCl2) and pre-incubated with or without
either NCJ or ascomycin alone (5 or 100 nM) for 15 min
at 37◦ before stimulation (either anti-IgE (1 µg/ml), fMLP
(100 nM) or buffer alone) for 30 min. Following centrifugation,
histamine content were determined in the supernatants and
lysed cell pellets by spectrofluorometric analysis based on the
method described by Shore et al. (1959). Histamine releases
were calculated by dividing histamine content in respective
supernatants by that present in equivalent cell lysates × 100%.
Frontiers in Pharmacology | www.frontiersin.org 2 March 2019 | Volume 10 | Article 333
fphar-10-00333 March 27, 2019 Time: 17:50 # 3
Yasinska et al. Nanoconjugate-Based Allergic Effector Cell Targeting
Net histamine releases were then calculated by subtracting
spontaneous secretions and the results then presented as
percentage inhibitions of net histamine release caused by
the stimulus alone.
Statistical Analysis
Each experiment was performed at least three times. When
comparing two events at a time we used a two-tailed Student’s
t-test. Multiple comparisons were performed by ANOVA test
and post hoc Bonferroni correction was applied. Statistical
probabilities (p) were shown in the figures as ∗ for p < 0.05; ∗∗
for p< 0.01 and ∗∗∗ for p< 0.001.
RESULTS
Our first objective was to characterize the NCJs using far-UV
CD spectra of the components, the materials and compounds
comprising the anti-CD203c- and ascomycin-conjugated AuNPs
(Figures 1A–F) by use of SRCD spectroscopy (Figure 1G). Our
observations confirmed that immobilization of both antibody
and the drug was successful.
Next, we compared the effects of NCJs and ascomycin alone
on histamine release from purified human basophils stimulated
either with anti-IgE (Figures 2A,B and Supplementary
Figures 1A,B) or the N-formylated tripeptide fMLP (Figure 2C
and Supplementary Figures 1C,D). In agreement with our
previous observations (Gibbs et al., 2014) NCJs containing
ascomycin and anti-CD203c substantially inhibited IgE-
dependent basophil histamine release and this level of
inhibition was similar to that seen with 100 nM ascomycin
alone. Our current results also include the effects of NCJs
without ascomycin, which did not show any inhibitory
properties. In contrast, NCJs were less effective at inhibiting
histamine release from basophils induced by fMLP, although
the inhibitory effects with NCJs were still significantly
greater than those seen with ascomycin alone at the highest
concentration (Figure 2C).
We next asked whether the striking inhibitory properties
of NCJs regarding the abrogation of IgE-dependent histamine
release from purified basophils were matched in unpurified
basophil preparations. Indeed, NCJs had similar inhibitory
effects in both preps, while ascomycin alone was less
effective (especially at the lower, 5 nM, concentration),
presumably due to specific basophil targeting by the NCJs
and greater distribution of the free drug between basophils and
contaminating peripheral blood mononuclear cells (Figure 2D
and Supplementary Figure 2).
Surprisingly, NCJs containing anti-CD203c were not effective
at inhibiting anti-IgE-induced histamine release from LAD2
mast cells (Figures 2E,F and Supplementary Figure 3).
The effects of ascomycin alone were also less effective
than previously observed for basophils, possibly owing to
requiring longer preincubation periods than for basophils.
Non-etheless, anti-CD203c-containing NCJ were even less
effective at inhibiting histamine release from LAD2 mast cells
than the moderate inhibition seen with ascomycin alone.
In contrast, when coupled to SCF, the inhibitory actions of
NCJ were restored to levels greater than seen for ascomycin
alone. We also observed that SCF-containing NCJs were
moderately (though significantly) effective at inhibiting basophil-
derived histamine release, though the inhibitory properties
were considerably less compared to anti-CD203c-containing
NCJs (Figure 2G).
FIGURE 1 | Characterization of nanoconjugates using synchrotron radiation circular dichroism (SRCD) spectroscopy. (A–F) Nanomaterials and compounds which
were analyzed using SRCD spectroscopy. (G) Observed far-UV spectra of anti-CD203c antibody, ascomycin and all possible types of functionalised gold
nanoparticles. Data are the mean values of four independent experiments.
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FIGURE 2 | Continued
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FIGURE 2 | Effect of NCJs on histamine release from human basophils and LAD2 mast cells. Cells were preincubated for 15 min either with NCJs, ascomycin or
buffer alone before stimulation for 30 min, after which histamine releases were assessed. All results are shown as percentage inhibition of histamine release ± SEM.
∗ and ∗∗ denote significant differences from control using a paired Student’s t-test (p < 0.05 or p < 0.01, respectively). Panel A Scheme illustrating the interaction of
a NCJ containing anti-CD203c with a human basophil and subsequent ascomycin delivery. Panel B Basophils stimulated with anti-IgE (n = 4). Results were first
corrected from spontaneous releases (5.4 ± 1.1%) and percentage inhibition calculated from net anti-IgE-induced release in the absence of NCJs or inhibitors
(25.3 ± 4.1%). Panel C Basophils stimulated with fMLP (n = 4). Results were first corrected from spontaneous releases (4.2 ± 1.2%) and percentage inhibition
calculated from net fMLP-induced release in the absence of NCJs or inhibitors (31.6 ± 4.0%). Panel D Comparison of the inhibitory effects of NCJs and ascomycin
alone in purified (>90% pure) and unpurified (<2% pure) human basophils stimulated with anti-IgE. Spontaneous histamine releases (4.6 ± 0.5% for purified
basophils, 3.2 ± 0.7% for unpurified basophils) were first subtracted and the results expressed as percentage inhibition of histamine release caused by anti-IgE
alone (net releases were 14 ± 2.7% for purified basophils, 14.2 ± 2.5% for unpurified basophils) (n = 8). Panel E Scheme illustrating interaction of a NCJ containing
SCF with LAD2 mast cell and subsequent ascomycin delivery. Panel F Effect of NJCs on histamine release from LAD2 cells stimulated with anti-IgE (n = 6). Results
were first corrected from spontaneous releases (15.7 ± 0.5%) and percentage inhibition calculated from net anti-IgE-induced release in the absence of NCJs or
inhibitors (15.9 ± 0.7%). Panel G Effect of different NJCs on histamine release from purified human basophils stimulated with anti-IgE. Results were first corrected
from spontaneous releases (4.0 ± 0.3%) and percentage inhibition calculated from net anti-IgE-induced release in the absence of NCJs or inhibitors (10.6 ± 1.0%).
DISCUSSION
Our SRCD spectroscopy results demonstrate that immobilization
of ascomycin and anti-CD203c on the gold surface of AuNPs
doesn’t affect the antibody secondary structure, based on
unchanged shape of the respective SRCD spectrum curves
(Figure 1G; successful immobilizations of targeting agents
on AuNPs is shown in Supplementary Figure 4). This
explains preserved biochemical activity of the antibody
upon its immobilization on the gold surface. This is
confirmed by the functional activities of the NCJs in
terms of targeting and inhibiting histamine release from
allergic effector cells. For basophils, this inhibitory action
was clearly due to the presence of ascomycin on the
NCJs, since no effects were observed using NCJs without
ascomycin conjugation. Furthermore, the inhibitory
actions of ascomycin were more pronounced in terms
of inhibiting IgE-dependent histamine release compared
to fMLP. As a result, ascomycin-containing NCJs were
also less effective at inhibiting fMLP-induced basophil
histamine release.
The concentration of ascomycin delivered into basophils
within the NCJs was maximally 5 nM, based on stoicheometrical
calculations on the number of ascomycin molecules fused
to each nanoparticle and the number of nanoparticles
incubated with basophils (Gibbs et al., 2014). The increased
inhibitory effect of these NCJs compared to incubation with
5 nM ascomycin alone supports that the NCJs facilitate
specific cellular targeting. Furthermore, we obtained the
same results with the NCJs in both pure and unpure
basophils preparations, whereas 5 nM ascomycin alone
displayed less inhibitory effects on unpure basophils than
pure basophils. This suggests that ascomycin, which is a
relatively lipophilic molecule, would otherwise disperse
into various cell populations in vivo, lowering its effective
concentration in basophils and increasing the likelihood
of side effects (thus emphasizing the need for cell-specific
targeting using NCJs).
In terms of the effects of NCJs on LAD2 mast cells, anti-
CD203c conjugation surprisingly failed to target these cells,
where no significant inhibition of IgE-dependent histamine
release was observed in contrast to ascomycin alone. Indeed,
we observed that LAD2 cells expressed barely detectable
levels of CD203c (Supplementary Figure 5A). This suggests
that CD203c may be absent in certain aberrant mast cell
disorders although it is be widely expressed both on a variety
of human primary mast cells as well as in vitro cultured
mast cells and other human mast cell lines (Ghannadan
et al., 2002; Andersen et al., 2008; Cop et al., 2017). The
LAD2 cell line is derived from a patient with mast cell
leukemia/sarcoma (Kirshenbaum et al., 2003). However,
neoplastic mast cells from systemic mastocytosis patients
have, in contrast to our observations with LAD2 cells,
been shown to overexpress CD203c (Hauswirth et al.,
2008). This would advocate the use of NCJs containing
anti-CD203c (or single chain antibodies/peptides against
this protein) to target most other human mast cells and
highlights the limitations of LAD2 mast cells in these
particular studies.
An alternative mast cell-specific marker is CD117 (KIT),
which binds SCF. Our results clearly showed, in contrast to
anti-CD203c-containing NCJs, that NCJs containing SCF
significantly inhibited LAD2 cell histamine release much
more than ascomycin alone. This verifies the concept of
specific drug delivery into mast cells using NCJs and shows
that CD117 could be used to specifically target mast cells
in tissues where other KIT-positive cells (present mainly in
the bone marrow) are absent. We assumed that basophils
could not be targeted with SCF-containing NCJs since, other
than during development, they are generally considered
to be CD117/KIT negative (Han et al., 2008). Indeed,
Western blot analysis of LAD2 and basophil lysates clearly
demonstrated high KIT expression in LAD2 mast cells
whereas it was undetectable in basophils (Supplementary
Figure 5B). However, SCF-containing NCJs still gave
rise to a moderate inhibition of histamine release from
basophils. This suggests that SCF may non-specifically
interact with some of the basophil cell surface-based
receptors or have a moderate affinity to some of them. The
second scenario is more likely given that SCF is known to
stimulate chemotaxis and the survival of peripheral blood
basophils (Heinemann et al., 2005).
We conclude that AuNP-based NCJs are highly effective
both at targeting human allergic effector cells and substantially
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blocking their function by delivering anti-allergic agents.
However, expensive stability as well as in vivo safety testing
will need to be conducted in before this technology can
be developed further as a new therapeutic approach in a
clinical setting.
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